Organization
SK Life Science
14 clinical trials
Clinical trial
A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset SeizuresStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1/2, Open-Label, Multicenter, Dose-Finding Study of SKL27969 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2024-03-01
Clinical trial
Open-Label Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Multicenter Open-Label Extension Study to Evaluate the Long-Term Safety of Cenobamate Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic SeizuresStatus: , Estimated PCD: 2025-05-01
Clinical trial
A Phase 1, Open-Label, Pharmacokinetic, Safety and Tolerability Study of a Single Oral Dose of Cenobamate (YKP3089) in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic ImpairmentStatus: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC SeizuresStatus: Recruiting, Estimated PCD: 2024-06-19
Clinical trial
Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut SyndromeStatus: Completed, Estimated PCD: 2022-12-14
Clinical trial
Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut SyndromeStatus: Completed, Estimated PCD: 2022-05-23
Clinical trial
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 mg Cenobamate Administered Orally as a Crushed Tablet or a Crushed Tablet Via a Naso-gastric Tube Compared With an Intact 200 mg Cenobamate TabletStatus: Completed, Estimated PCD: 2023-01-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label ExtensionStatus: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-10-27
Clinical trial
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyStatus: Not yet recruiting, Estimated PCD: 2027-05-26
Clinical trial
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresStatus: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label ExtensionStatus: Recruiting, Estimated PCD: 2025-06-01